A GUIDE TO

ALPHA-1 ANTITRYSIN DEFICIENCY
DO YOU OR YOUR FAMILY MEMBERS SUFFER ANY OF THESE CONDITIONS?

- Asthma
- Jaundice
- Early onset emphysema
- Abnormal liver function
- Chronic bronchitis
- Recurrent chest colds
- Chronic Obstructive Pulmonary Disease (COPD)
- A family history of lung or liver issues

YOUR CONDITION COULD BE CAUSED BY AN HEREDITARY CONDITION KNOWN AS ALPHA-1 ANTITRYPSIN DEFICIENCY, OR A1AD.

The Alpha-1 Association of Australia (AAA) is an organisation dedicated to the help and support of Australians who are affected by and interested in A1AD.
A1AD is a genetic disorder which can cause lung or liver disease in children and adults.

A1AD is one of the most common hereditary disorders in the world, but it often remains undiagnosed.

Knowing that you have A1AD gives you the opportunity to avoid risk factors and to make positive lifestyle changes which, together with the right medical care, can help to improve your quality of life.

Everyone’s liver produces the protein alpha-1 antitrypsin, or AAT. An important function of AAT is to protect the lungs. In people with A1AD, the AAT is malformed and cannot be released by their liver. A1AD occurs when there is a deficiency of AAT in the bloodstream.

AAT also protects delicate lung tissue from an enzyme known as neutrophil elastase. The normal function of neutrophil elastase is to remove inhaled material which has entered the respiratory system, such as smoke and other pollutants.

In the absence of AAT, neutrophil elastase will attack the harmful material as well as healthy lung tissue. Most commonly, this leads to lung disease, however, the build up of AAT in the liver can also lead to liver disease.

The deficiency can cause problems with the pancreas and is associated with the skin disease panniculitis. However, problems with the lungs, and to a lesser degree the liver, are far more common.

Not everyone who has A1AD will develop symptoms. We still don’t know why this is so, but we do know that early detection, treatment and lifestyle changes can make a dramatic difference in the progress of disease.

As a result, the sooner a diagnosis is made, the more effective lifestyle and treatment options will be.
As a genetic condition, A1AD is passed from parents to children through genes. Everyone has two AAT genes, both being normal in most people. Those who suffer symptoms of A1AD may have either one normal and one defective gene (known as carriers), or two defective genes.

Approximately 1 in 50 people worldwide have at least one defective gene*. The severity of the disease varies between individuals, as AAT levels in the bloodstream may range between zero-80% of normal levels, depending on the number and type of affected genes an individual has.

* Estimate based on data from:
de Serres (2002), Chest, v. 122, p 1818-1829
A1AD affects people in different ways and symptoms can vary between individuals. Some common early symptoms associated with lung or liver dysfunction include:

- Shortness of breath
- Decreased exercise tolerance
- Recurrent chest colds or respiratory/lung infections
- Chronic coughing and/or wheezing
- Excess sputum (phlegm)
- Asthma which is not responsive to treatment
- History of suspected allergies
- Abdominal swelling
- Abnormal liver function tests or unexplained liver problems
- Enlarged liver or spleen
- Skin lesions or inflammation
- Jaundice

The World Health Organisation makes the following recommendation with regard to testing for A1AD:

“It is therefore recommended that all patients with COPD and all adults and adolescents with asthma be screened once for AAT deficiency. Those with abnormal results on screening should have Pi (genetic) typing.”
If you suffer from any symptoms listed in this brochure, you can ask your doctor for a simple blood test which is covered by the Medicare Benefits Scheme. The Medicare schedule numbers for A1AD testing are as follows:

66635 - Quantitation in serum, urine or other bodily fluids

66638 - Isoelectric focussing or similar methods for determination of alpha-1 antitrypsin deficiency phenotype in serum

66635 will measure the level of AAT in your bloodstream. Low AAT levels may indicate a need for phenotyping (66638) or DNA testing to assess your individual AAT genetic makeup.

If you have a relative who has been diagnosed with A1AD, or a family history of early emphysema or liver disease, phenotyping or DNA testing is recommended regardless of your AAT levels. This is because AAT levels alone do not necessarily reveal your AAT genetic status. Knowledge of AAT levels in conjunction with knowledge of your AAT genetic status allows a more complete understanding of the implications for you and your children or future children.

Some with A1AD may present without obvious symptoms and lead relatively healthy lives, especially if smoking is avoided. However, they still risk passing the defective gene on to their children.

Those seeking A1AD diagnosis for themselves or family members should carefully consider health and life insurance complications, for example an insurer’s requirement for disclosure of known pre-existing illnesses.
Every human being is made up of many pairs of genes, and for each pair, we inherit one from each parent.

Pi stands for protease inhibitor, of which AAT is just one. A ‘normal’ person is referred to as PI MM, i.e. they have two normal genes, which means they produce a normal supply of AAT.

Sometimes a faulty gene is thrown into the mix. The most common abnormal gene is referred to as the Z gene (there are other variants, but since they all follow the same pattern, we’ll stick with the Z). For someone to be PI ZZ, a faulty gene must have been inherited from each parent, which means each parent must have had at least one Z gene (usually MZ).

A1AD occurs when both parents pass on an abnormal gene to their child. A mother and father who are both carriers, (eg. MZ), have a 50% chance of their child being a carrier, 25% chance of having a child without A1AD, (MM), or 25% probability of having a child with A1AD, (eg. ZZ). The same percentages apply for each child. Therefore, it is possible for an MZ father and an MZ mother to have four children, all of who are ZZ or all of who are MM. On the other hand, it is possible for this same father and mother to have 1 ZZ child, 2 MZ children and 1 MM child, as the percentages imply. If one parent has the ZZ phenotype, and the other has two normal copies of the gene (MM), all of their children will have the MZ phenotype.

See example in the diagram above.
TREATMENT OF A1AD

Augmentation therapy aims to supplement the deficiency of AAT in a patient by infusion or inhalation of purified AAT extracted from human blood plasma. Augmentation therapy has not yet been approved for use in Australia, however, clinical trials are underway. Augmentation is available in several other countries.

TREATMENT OF SYMPTOMS

Treatment of the symptoms associated with A1AD are many and varied, depending on the symptom. It is vital that the doctors involved with your care are aware of your A1AD status, and the need to consider action at the first sign of related symptoms, for example bringing respiratory infections under control, in order to minimise long term damage.

ORGAN TRANSPLANTATION AND OTHER SURGICAL PROCEDURES

Should your A1AD lead to severe lung or liver damage, a lung or liver transplant, or lung reduction therapy, may be an option for you.
Early diagnosis of A1AD represents an opportunity to take steps to avoid risk factors, limit symptoms, or slow the progression of symptoms you may already be experiencing.

One of the things you should know is exactly which A1AD genes you have. Without that knowledge, it is difficult to know how the diagnosis will affect either you or your family.

Not everyone with A1AD will develop symptoms. Even if you do experience symptoms, proper treatment by your doctors and lifestyle changes may significantly increase the quality and quantity of your life.
HOW CAN I IMPROVE MY CHANCES OF STAYING HEALTHY?

• Seek periodic liver and respiratory tests in order to help early identification of symptoms and to monitor progress

• Avoid cigarette smoking, fumes, dust, and other polluted environments, especially for extended periods, such as industrialised workplaces generating poor air quality

• Seek early treatment for lung infections and colds

• Seek your doctor’s guidance in relation to vaccinating yourself against infectious diseases which may exacerbate the effects of A1AD

• Ensure you have regular immunisations against influenza and pneumonia

• Stay fit with regular exercise

• Maintain a balanced diet

• Moderate, if not eliminate, intake of liver toxins such as alcohol

• Avoid non-essential intake of drugs - some over-the-counter drugs and certain prescribed medications can harm the liver

• Moderate, if not eliminate, intake of liver toxins such as alcohol

• Avoid non-essential intake of drugs - some over-the-counter drugs and certain prescribed medications can harm the liver
To help the AAA meet its objectives, donations can be made via www.alpha1.org.au

CONTACT DETAILS
Alpha-1 Association of Australia
www.alpha1.org.au
emailus@alpha1.org.au
Disclaimer: The information published by the AAA is a guide only, and is not intended to be a substitute for professional medical or legal advice. The AAA, its officeholders and its members disclaim all liability from reliance placed on the information herein. For medical advice, please consult your physician. For legal advice, please consult your lawyer.